Background. Increasing azithromycin usage and resistance in Neisseria gonorrhoeae threatens current dual treatment. Because antimicrobial exposure influences resistance, we analyzed the association between azithromycin exposure and decreased susceptibility of N. gonorrhoeae.
We excluded patients who reported antibiotic use prescribed outside the STI clinic in the 3 months preceding gonorrhoea diagnosis. We included 1 episode and 1 isolate per patient. If a patient had both exposed and unexposed episodes, we included the exposed episode. In case of multiple exposed or multiple unexposed episodes, we included the most recent episode. In case of multiple N. gonorrhoeae isolates per episode (because of multiple infected anatomical sites), we included the isolate with the highest minimum inhibitory concentration (MIC) for azithromycin. Baseline and clinical characteristics were obtained from the electronic patient file. Because we used routinely acquired data and samples, no informed consent was required.
Due to azithromycin's half-life, we also considered time since exposure to be of possible influence. Therefore, the cohort of patients was divided into the following 3 exposure groups: those unexposed in the previous 60 days, those exposed in the previous 31-60 days, and those exposed in the previous 30 days.
Determination of Azithromycin Susceptibility
Neisseria gonorrhoeae isolates were retrieved from storage, inoculated on chocolate agar, and incubated at 37°C in a 5% CO 2 -enriched atmosphere. A 0.5 (0.45-0.55) McFarland standard solution of isolates in phosphate-buffered saline was inoculated on GC-agar plates. Azithromycin MICs were determined using Etest as instructed by the manufacturer (bioMérieux SA, Marcyl'Etoile, France).
Whole Genome Sequencing and Molecular Typing
To determine the correlation of azithromycin exposure with sequence type (ST) and molecular resistance markers, we performed whole genome sequencing (WGS) analysis. We selected all 14 isolates from patients exposed ≤30 days and 14 unexposed isolates that were frequency matched for MIC and year of isolation. From exposed patients with gonorrhoea at the t -1 clinic visit, the t -1 isolates were selected as well.
These 31 isolates were sent to the National Microbiology Laboratory of the Public Health Agency of Canada for WGS as previously described [13, 14] . In brief, DNA samples were extracted from cultures following standard protocol using Epicentre Masterpure Complete DNA and RNA Extraction Kit (Mandel Scientific, Guelph, Ontario). Libraries were created with TruSeq sample preparation kits (Illumina, San Diego, California) and sequenced on the Illumina MiSeq platform (Illumina), yielding an average of 1 383 601 reads/genome and average genome coverage of 186X. Quality reads were assembled with SPAdes and annotated with Prokka. There was an average of 59.1 contigs per isolate and an average contig and N50 length of 37 728 and 87 813 nucleotides, respectively. A core single nucleotide variation (SNV) phylogeny was created, with the assembled contigs file of isolate 28 as a mapping reference and a custom Galaxy SNVPhyl workflow (https://github.com/ phac-nml/snvphyl-galaxy). Highly recombinant regions with >10 SNVs per 100 nucleotides were removed from the analysis. A meta-alignment of informative core SNV positions was used to create a maximum likelihood phylogenetic tree, and phylogenetic clades were determined by cluster analysis using a genetic distance threshold of 4.5%. The percentage of valid and included positions in the core genome was 39.2%, and 4383 sites were used to generate the phylogeny. WGS read data were submitted to the NCBI Short Read Archive under BioProject ID PRJNA348107.
Neisseria gonorrhoeae multiantigen sequence types (NG-MAST), multilocus sequence types (MLST), and molecular markers associated with azithromycin resistance were determined in silico. Sequences were submitted to the NG-MAST website (www.ng-mast.net) and the MLST website (pubmlst.org/neisseria) to assign STs [14, 15] . The selected resistance markers included C2611T and A2059G mutation of the 23S rRNA gene (Escherichia coli numbering), presence of erm, mtrR -35A deletion, mtrR A39T, and mtrR G45D. Mutations of 23S rRNA were determined using the core SNV pipeline and N. gonorrhoeae NCCP11945 as a mapping reference [13] . PenA types were determined by submitting sequences to Neisseria gonorrhoeae Sequence Typing for Antimicrobial Resistance (NG-STAR) (https://ngstar.canada.ca).
Statistical Analyses
Baseline characteristics, geometric mean MICs, STs, and molecular markers were compared using χ 2 , Fisher exact, or Kruskal-Wallis testing. Year of infection was used continuous or categorized into 5-year groups (1999-2003, 2004-2008, and 2009-2013) , if applicable. The association between azithromycin exposure and MIC (transformed to its natural logarithm) was determined using multivariable linear regression analysis. The multivariable analysis included all variables with a univariable P < .05. Stepwise backward selection was performed to obtain the final model. In case of correlated variables (such as sexual orientation, anatomical site, and human immunodeficiency virus [HIV] status), we included the variable of most clinical interest.
Given the half-life of azithromycin, the effect of subtherapeutic azithromycin concentrations is expected to be most profound in the first month after treatment. Therefore, we performed a subanalysis that was restricted to patients with a t -1 clinic visit in the 30 days before gonorrhoea diagnosis. All analyses were performed using Stata (version 13; StataCorp, College Station, Texas).
RESULTS

Included Patients and N. gonorrhoeae Isolates
At the Amsterdam STI clinic, 340 592 consultations were recorded in 1999-2013. After applying the inclusion and exclusion criteria, 395 patients with 1 isolate were included ( Figure 1 ). Antimicrobial susceptibility could not be determined for 72 isolates, which were excluded. This resulted in 14 patients exposed to azithromycin ≤30 days, 97 patients exposed between 31 and 60 days, and 212 patients unexposed to azithromycin at t -1 .
Baseline Characteristics
Patients were predominantly MSM (n = 235, 73%) and of Dutch ethnicity (n = 209, 65%). The median age was 33 years (interquartile range, 26-41 years). A total of 231 patients (72%) reported a previous gonorrhoea diagnosis and 209 (65%) reported a previous chlamydia diagnosis. The exposure groups differed significantly for sexual preference (P = .02), infection site (P < .001), HIV status (P = .008), and year of infection (P < .001; Table 1 ). Unexposed were more often HIV-positive MSM with a rectal infection and included recently (2009-2013) compared to exposed individuals. Among those patients exposed ≤30 days, 4 (29%) also had gonorrhoea at t -1 compared to 51 (53%) patients exposed at 31-60 days and 10 (5%) unexposed. All patients with gonorrhoea at t -1 were also treated with ceftriaxone or cefotaxime. There was no significant difference in MIC at t 0 between those with gonorrhoea at t -1 (mean, 0.28 mg/L; range, <0.016-12) and those without gonorrhoea at t -1 (mean, 0.28 mg/L; range, 0.032-24; P = .7).
Azithromycin Susceptibility
The geometric mean azithromycin MIC was 0.28 mg/L (range, <0.016-24) and differed significantly by sexual preference (P < .001), site of infection (P = .01), ethnicity (P < .001), HIV status (P = .004), and time period of infection (P = .005; Table 2 Figure 2 shows the azithromycin MIC by time since t -1 for each exposure group. Univariable linear regression showed a significant association between azithromycin MIC and exposure group (P = .03), age (P < .001), ethnicity (P < .001), sexual orientation (P < .001), year of infection (P = .03), anatomical site of infection (P = .04), and HIV status (P = .03; Table 3 ). Anatomical site of infection and sexual preference were correlated (only women provided cervical samples), as were HIV positivity and sexual preference (all but 1 HIV-positive patient were MSM). Because anatomical site was of more clinical interest, only this was included in the multivariable analysis. When we adjusted for age, ethnicity, anatomical site, and year of infection, we found a significant association between exposure group and azithromycin MIC (P = .002). Patients exposed to azithromycin ≤30 days had isolates with significantly higher azithromycin MICs (β, 1.00; 95% confidence interval [CI], 0.44-1.56; P = .001) compared to unexposed. This means that the mean MIC of isolates from patients exposed ≤30 days was 2.7 times higher than that from unexposed. The mean MIC from isolates of patients exposed at 31-60 days was not significantly different compared to unexposed (β, 0.07; 95% CI, −0.19 to 0.33; P = .6).
Determinants of Azithromycin MIC
We noted a possible outlier among the exposed ≤30 days group (MIC, 24 mg/L; Figure 2 ). When this outlier was excluded, the association between exposure ≤30 days and azithromycin MIC remained significant (β, 0.75; 95% CI, 0.17-1.32; P = .04).
We performed the same multivariable analysis and adjusted for sexual preference instead of anatomical site. The association between exposure ≤30 days and MIC was significant (β, 0.95; 95% CI, 0.40-1.51; P = .003), also it was significant when the outlier was excluded (β, 0.70; 95% CI, 0.13-1.27; P = .049).
Subgroup Analysis
A subanalysis restricted to patients (exposed and unexposed) with a t -1 clinic visit ≤30 days preceding t 0 (n = 71) showed a significant association between azithromycin exposure and MIC (β, 1.08; 95% CI, 0.43-1.74; P < .001). This effect remained significant when the possible outlier was excluded (β, 0.76; 95% CI, 0.12-1.40; P = .01).
Because those exposed ≤30 days did not include any women, we performed a subanalysis restricted to men (n = 285). The association between exposure to azithromycin ≤30 days and MIC was significant (β, 0.98; 95% CI, 0.44-1.52; P = .002), also it was significant when the outlier was excluded (β, 0.72; 95% CI, 0.17-1.27; P = .04).
Phylogenomic Analysis
We selected 31 isolates for WGS: 14 from patients exposed ≤30 days, 14 unexposed, and 3 t -1 isolates. One other t -1 isolate was nonviable. The 31 isolates were obtained from 28 patients: 20 MSM (71%), 5 heterosexual males (18%), and 3 females (11%); the majority were Dutch (n = 19, 68%; Figure 3 We identified 15 NG-MAST STs, of which ST2992 was most common (n = 7, 23%); all other types were found in 1 or 2 strains. Three isolates had sequences that were not reported previously and were assigned ST numbers 500-502. We identified 10 MLSTs, of which ST9363 was most common (n = 8, 26%), followed by ST1901, ST1584, and ST12396 (n = 3, 10% each); 1 could not be typed due to a missing pdhC gene. The most common penA type was II (n = 18, 58%), and 1 (3%) was a mosaic penA type XXXIV.
We noted no A2059G mutations; C2611T mutations of 23S rRNA were observed in 7 isolates (23%), consisting of 1 mutated allele (n = 1), 3 alleles (n = 3), or 4 alleles (n = 3). All isolates with at least 3 mutated alleles were resistant to azithromycin. The isolate with 1 mutated allele had an MIC of 0.38 mg/L. An ermB gene was present in 1 isolate (3%), which had a wildtype 23S rRNA, an A39T mtrR mutation, and azithromycin MIC of 0.5 mg/L. Mutations in mtrR were noted in 28 isolates; 10 (36%) had a -35A deletion, 13 (46%) had an A39T mutation, and 8 (29%) had a G45D mutation. Among isolates with an A39T or G45D mutation, the geometric mean azithromycin MIC was 0.84 mg/L compared to 0.35 mg/L for isolates without these mutations (P = .08). A39T or G45D mutations were significantly more often seen among isolates from patients exposed ≤30 days (n = 12, 86%) compared to unexposed isolates (n = 6, 43%; P = .046). No significant associations between exposure to azithromycin and 23S rRNA mutations were observed.
WGS analysis grouped 19 isolates into 5 clades (clades A-E; Figure 3 ); 12 isolates were outside these lineages. The largest clade (clade A, n = 10) consisted of MLST ST9362, ST9363, ST12396 and NG-MAST ST2992, ST5108, and ST4751 and contained only recent isolates collected from 2009 to 2013. Phylogenetic clustering of molecular markers was seen for penA type II isolates, which were predominantly located in clades A-B, while other penA types grouped into other clades and subclades. The mtrR -35A deletion was predominantly seen in isolates of clades C-E, whereas the A39T and G45D mutations were found in isolates of clades A and B, respectively. All azithromycin-resistant isolates were located in clade A and possessed a C2611T mutation in at least 3 alleles of 23S rRNA. Azithromycin exposure status did not cluster and was distributed throughout the phylogeny. When ≤30 day exposure was compared to unexposed, no significant differences of In case of multiple N. gonorrhoeae isolates per patient, only the isolate with the highest azithromycin minimum inhibitory concentration (MIC) was included.
Abbreviations: β, regression coefficient for the natural logarithm of the azithromycin MIC; Ref, reference category; t 0 , clinic visit of Neisseria gonorrhoeae culture; t -1 , clinic visit in 60 days preceding t 0 with (or without) azithromycin exposure. a All variables with P < .05 in univariable analysis were included in the multivariable analysis, stepwise backward selection was performed to obtain the final multivariable model.
b Unless otherwise specified.
c Per year of infection; no isolates from 2005 were included (lost in laboratory).
d Ever reported gonorrhoea or chlamydia infection, 1 missing.
NG-MAST (P = .12), MLST (P = .08), or penA types (P = .07) were observed. The 3 pairs of patients who were exposed to azithromycin ≤30 days and with gonorrhoea at t -1 had both t -1 and t 0 isolates tested with WGS. The first pair of isolates (501 and 106) was phylogenetically distant with different molecular profiles, indicating that the second infection was with a different strain. The second (502 and 191) and third pair (500 and 28) clustered closely. Each pair had identical molecular profiles, suggesting a reinfection with the same strain, probably from an untreated sex partner. The paired isolates 500 and 28 (from a heterosexual male) were identical to isolate 29 (from a female commercial sex worker); clinic visits of these patients were 1 week apart. However, we could not establish a partner link to confirm sexual contact between these patients.
DISCUSSION
Here, we describe an association between exposure to azithromycin and decreased azithromycin susceptibility of N. gonorrhoeae in humans. Azithromycin MICs were significantly higher in isolates from patients exposed to azithromycin ≤30 days before gonorrhoea diagnosis compared to patients treated 31-60 days previously and to those not treated with azithromycin. Only 2 previous case reports have described an increase in azithromycin MIC after treatment with azithromycin, while MICs for other antimicrobials remained at pretreatment levels [16, 17] . In other studies, azithromycin-susceptible isolates were exposed to different concentrations of erythromycin in vitro, after which high-level resistance associated with 23S rRNA mutations developed rapidly [18, 19] . Furthermore, pharyngeal macrolide-resistant viridans streptococci were more often found after treatment with macrolides, including azithromycin [20] . It is suggested that exposure of N. gonorrhoeae to low concentrations of azithromycin can induce an increase in MICs, as was demonstrated for erythromycin, or cause selection of strains with an increased MIC [4, 6, 19, 21, 22] . Although we were unable to evaluate molecular resistance markers for all isolates, WGS was performed to compare a subset of exposed and unexposed isolates. Phylogenetic analysis did not indicate any genetic relatedness based on azithromycin exposure. In addition, azithromycin exposure was not significantly associated with 23S rRNA mutations, suggesting that these mutations arose independently of exposure and spread clonally. However, A39T or G45D mutations of mtrR were significantly more common among isolates from patients exposed to azithromycin. This suggests that subtherapeutic levels of azithromycin might induce or select for strains with these mutations. Our results indicate that higher MICs in strains from patients exposed to azithromycin were not caused by selection of a specific WGS clade, or MLST or NG-MAST type, but that acquisition or selection of specific mutations, possibly including mtrR, is responsible for this effect. Future studies should be conducted to confirm our results and to identify what effect azithromycin treatment has on molecular resistance determinants in N. gonorrhoeae.
The current study has potential limitations. Sixty-five patients (20%) also had gonorrhoea at t -1 . If treatment at t -1 failed due to azithromycin resistance, this may have caused selection bias. Because all were treated with cephalosporins and mean MICs at t 0 were not different, we considered this highly unlikely. To prevent recall bias or incorrect classification of exposure, we only included azithromycin prescribed by the STI clinic and excluded those who reported recent use of antibiotics prescribed elsewhere. Therefore, the influence of azithromycin exposure from other sources (general practitioners or medical specialists) was not taken into account. We expect that azithromycin prescribed for respiratory tract infections could have increased N. gonorrhoeae MICs. If such strains were misclassified in our study as unexposed, the association of azithromycin exposure and MIC is an underestimation of the real result. Furthermore, there was 1 influential MIC outlier, but the association remained significant when this outlier was excluded. Finally, the sample size of isolates from patients exposed to azithromycin in the previous 30 days was small, despite an inclusion period of 14 years. More isolates would be needed to find significant associations between exposure and molecular determinants of higher MICs.
Azithromycin is widely administered for C. trachomatis and nonspecific urethritis in patients at high risk for STIs [1, [7] [8] [9] . Moreover, most guidelines recommend dual therapy that includes azithromycin for the treatment of gonorrhoea [1, 2, 10] . In light of emerging antimicrobial-resistant N. gonorrhoeae and lack of evidence-based alternative treatment options for multidrug-resistant strains, prudent use of antibiotics is warranted [6] . The current results add evidence to the possible negative effects of azithromycin on resistance formation in N. gonorrhoeae. As it is unclear whether dual therapy decreases selection pressure and the first treatment failure of dual therapy is reported, the use of azithromycin in dual therapy for gonorrhoea and in syndromic management of urethritis might need reevaluation [3, 4, 6] . Moreover, research into new antimicrobial drugs and the potential of currently available antibiotics for the treatment of gonorrhoea needs to be intensified. Future studies on the association between azithromycin exposure and resistance should focus on high-risk patients and molecular markers for resistance. Studies should include patients exposed to azithromycin in the previous month and azithromycin prescribed by healthcare institutions other than STI clinics.
In conclusion, our results show a significant association between exposure to azithromycin and higher azithromycin MICs in N. gonorrhoeae, without the selection of specific resistant genotypes. These results suggest that frequent use of azithromycin in patients at high risk of contracting N. gonorrhoeae infections induces an increase in MIC, possibly caused by mutations of mtrR, which may result in clinical resistance.
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